Status:

COMPLETED

Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma

Lead Sponsor:

Beth Israel Deaconess Medical Center

Collaborating Sponsors:

Massachusetts General Hospital

Dana-Farber Cancer Institute

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The main purpose of this study is to test the safety and determine the type and severity of any side effects of the Dendritic Cell Fusion Vaccine given in combination with an autologous transplant for...

Detailed Description

* The first group of participants on this study will receive up to 3 monthly doses of the study vaccine beginning about 1 month following the autologous transplant. If this is found to be safe, the ne...

Eligibility Criteria

Inclusion

  • Patients with multiple myeloma who are potential candidates for high dose chemotherapy
  • Measurable disease as defined by a history of an elevated M component in plasma, urine, or free kappa/lambda light chains in the serum
  • 18 years of age or older
  • ECOG Performance Status of 0-1 with greater than a nine week life expectancy
  • Patients with \> 20% bone marrow involvement or plasmacytoma amenable to resection under local anesthesia
  • Negative pregnancy test, and adequate contraception method
  • DLCO (adjusted)\> 50%
  • Cardiac Ejection Fraction \> 45%
  • Laboratory values within the ranges outlined in the protocol

Exclusion

  • History of clinically significant venous thromboembolism
  • Clinically significant autoimmune disease
  • HIV positive
  • Serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
  • Pregnant or lactating women

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2020

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT00458653

Start Date

April 1 2005

End Date

July 1 2020

Last Update

June 22 2023

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02114

2

Dana-Farber Cancer Institute/Brigham & Women's Hospital

Boston, Massachusetts, United States, 02115

3

Massachusetts General Hospital

Boston, Massachusetts, United States, 02215

4

Rambam Medical Center

Haifa, Israel, 31096